The strychnine-sensitive glycine receptor (GlyR) mediates inhibitory synaptic transmission in the spinal cord and brainstem and is linked to neurological disorders, including autism and hyperekplexia. Understanding of molecular mechanisms and pharmacology of glycine receptors has been hindered by a lack of high-resolution structures. Here we report electron cryo-microscopy structures of the zebrafish a1 GlyR with strychnine, glycine, or glycine and ivermectin (glycine/ivermectin). Strychnine arrests the receptor in an antagonist-bound closed ion channel state, glycine stabilizes the receptor in an agonist-bound open channel state, and the glycine/ivermectin complex adopts a potentially desensitized or partially open state. Relative to the glycine-bound state, strychnine expands the agonist-binding pocket via outward movement of the C loop, promotes rearrangement of the extracellular and transmembrane domain 'wrist' interface, and leads to rotation of the transmembrane domain towards the pore axis, occluding the ion conduction pathway. These structures illuminate the GlyR mechanism and define a rubric to interpret structures of Cys-loop receptors.
Neurotransmitter-gated ion channels mediate fast excitatory and inhibitory signal transduction in the central nervous system (CNS) by controlling ion flux through neuronal cell membranes in response to the binding of a wide range of neurotransmitters 1 . Glycine, a major inhibitory transmitter in the CNS 2 , exerts its inhibitory effect on the glycine receptor (GlyR), a postsynaptic ligand-gated channel receptor, opening a chloride-permeable pore that, in turn, leads to hyperpolarization of the membrane potential and inhibition of neuronal firing [3] [4] [5] [6] . GlyRs mediate neurotransmission throughout the spinal cord and brain stem and control a wide range of motor and sensory functions including vision and audition [6] [7] [8] . Heritable mutations of human GlyR are the major cause of a rare neurological disorder, hyperekplexia (startle disease) 9, 10 . Strychnine, the notoriously toxic and complex alkaloid 11 , is a potent competitive GlyR antagonist that locks the receptor in a closed state, precluding chloride permeation. Used to facilitate receptor isolation 12 , and exploited to disentangle glycine-induced synaptic currents, strychnine acts at the intersubunit, canonical neurotransmitter site 13 . Glycine binds at the same site as strychnine yet promotes channel opening, allowing permeation of chloride ions through an anion conductive pathway with an estimated diameter of 5.2-6.0 Å 14, 15 . Small molecules and ions, including the macrocyclic lactones ivermectin and related avermectins, modulate the gating activity of GlyRs by potentiating glycine-induced currents by an allosteric mechanism 16 . Despite the important roles of GlyRs in the CNS and their prominence in neuroscience, mechanisms to describe the action of strychnine, glycine and ivermectin in terms of atomic structure have proven elusive.
GlyRs belong to the superfamily of Cys-loop receptors that includes the cation-selective nicotinic acetylcholine receptor (nAChR) and the serotonin type-3 receptor (5-HT 3 R), as well as the anion-selective GABA type A receptor (GABA A R) 17, 18 . As a result of landmark studies 1 , Cys-loop receptors have been studied because of their prominent roles in the nervous system and because they are targets of scores of natural products and synthetic agents, from curare to valium. More recently, high-resolution structures of the prokaryotic pentameric ligand-gated ion channels, GLIC and ELIC [19] [20] [21] [22] , and a chimaeric GLIC-GlyR protein termed Lily 23 , as well as the eukaryotic nAChR 24, 25 , GluCl 26, 27 , 5-HT 3 R 28 , and GABA A R 29 have been elucidated. Molecular understanding of eukaryotic Cys-loop receptors, however, is largely based on comparisons between different receptors 30, 31 due to the challenge of capturing a single receptor in multiple functional states. To reveal the molecular interplay between competitive antagonists, agonists or allosteric modulators and ion channel gating, we determined GlyR structures in complex with strychnine, glycine, or glycine and ivermectin (referred to here as glycine/ivermectin) using single-particle electron cryo-microscopy (cryo-EM).
Structure determination and refinement
The three-dimensional reconstructions of the strychnine-, glycine-, and glycine/ivermectin-bound structures have estimated resolutions of 3.9, 3.9, and 3.8 Å , respectively (Extended Data Figs 1-3), and are of sufficient quality to allow modelling of almost the entire receptor ( Fig. 1 and Extended Data Fig. 4 ). The density for strychnine can be recognized in the strychnine-bound form, and is located at the intersubunit neurotransmitter-binding pocket. By contrast, density for glycine is not discernable in either the glycine-or the glycine/ ivermectin-bound forms. Characterized by the distinctive triangular shape of its macrocyclic lactone, the density of ivermectin is unambiguous, and is found wedged between transmembrane domain (TMD) subunit interfaces. The pore-lining M2 helix is best resolved in the glycine/ivermectin-and strychnine-bound structures (Extended Data Fig. 4c ), although three (Ala326-Thr328) and two (Gly327-Thr328) residues are not visible in the M3-M4 loop of the strychnine-and glycine-bound reconstructions, respectively (Extended Data Fig. 4d ). The final structures have excellent stereochemistry (Extended Data Table 1 ) and correlate well with the respective density maps (Extended Data Figs 1-3 ).
Overall architecture
The three GlyR structures have urn-like architectures, similar to the AChR 25 and other Cys-loop receptors, with the pentameric assemblage of subunits surrounding a central fivefold symmetric pore axis. Each subunit has the shape of an upright left forearm, wearing a mitten (Extended Data Fig. 5 ). The b-strands of the extracellular domain (ECD) form the palm and the hallmark C loop emerges as the thumb, poised on the back of the hand of an adjacent subunit. A 'wrist-like' cuff connects the ECD and TMD and is buttressed by 'ligaments' that include the pre-M1 linker and loops of the ECD and TMD. We envision the TMD as the 'forearm', consisting of helices M1-M4. With the open palm and thumb of one mitten packing against the back of the hand of the neighbour, together with multiple interactions via the TMD forearms, these interactions knit the pentamer together ( Fig. 1d-f) .
The outline of the strychnine-GlyR TMD is approximately perpendicular to the membrane (Fig. 1a, d ). By contrast, in the glycine-GlyR complex, the extracellular half of TMD is wider than the intracellular half (Fig. 1b, e) , reminiscent of a truncated cone. In the glycine/ivermectin-GlyR structure, the intracellular halves of the TMs move closer to each other (Fig. 1c, f) . Thus, the pore in the strychnine-bound form is constricted throughout and the pore-lining M2 helices are perpendicular to the membrane, in comparison with the other two forms (Fig. 1g-i ). In the glycine-bound form, the extracellular opening is wider than in the strychnine complex because the M2 helices tilt and undergo an anticlockwise rotation around the pore axis (viewed from the extracellular side). The binding of ivermectin promotes a clockwise rotation of the intracellular half of the M2, relative to the glycine-bound form, constricting the intracellular opening of the pore but leaving the extracellular entry as expanded as in the glycine-bound structure.
Ion channel pore
Inspection of the three GlyR structures demonstrates that there are two physical sites of constriction within the ion channel pore located at 229Pro (Pro266) and 99Leu (Leu277), highly conserved residues that reside on the M2 helix and are located near the cytoplasmic side and the middle of the helix, respectively. The descending order of pore cross-sectional area, as estimated by the distance between adjacent C a atoms of 229Pro residues, is glycine, strychnine, glycine/ivermectin, while at the position of the 99Leu, the order is glycine, glycine/ivermectin, strychnine (Fig. 2a-c) . The ion channel in the strychninebound form is the narrowest, with a radius of ,1.4 Å at 99Leu, too narrow for passage of a dehydrated chloride ion with an ionic radius of 1.8 Å 32 . In the glycine-and glycine/ivermectin-bound structures, 99Leu rotates away from the five-fold axis, expanding the ion channel pore to a radius of 4-5 Å . In the glycine-bound form, the smallest radius is 4.4 Å at 229Pro, allowing permeation of hydrated chloride ions, with an ionic radius of 3.3 Å . Thus the strychnine-bound form is an antagonist-bound closed non-conducting state and the glycinebound form is an agonist-bound open conducting state (Fig. 2e-j) .
To define the structural mechanism underlying the changes in dimension and shape of the ion channel pore, we measured the 'tilt' (h) and rotation angles (w) of the pore-lining M2 helices relative to the pore axis (Fig. 2d) . The tilt angle h is approximately the same in the glycine and glycine/ivermectin complexes and larger than in the strychnine form, thus opening the extracellular 'halves' of the ion channel pores in the glycine-and glycine/ivermectin-bound forms nearly twofold and 99Leu, viewed from the cytoplasmic side, with their C a in cyan and magenta spheres, respectively. Distances are in ångstroms. d, Plot of the porelining M2 as represented by the vector connecting 229ProC a and 99LeuC a , with 229ProC a as the origin, the tilt angle h and the rotation angle w relative to the pore axis. The w of strychnine-bound GlyR is set to zero. e-g, Sagittal 'slice' views along the pore axis. h-j, Shape and size of the ion permeation pathway. M2 of two subunits are shown as ribbon representation and the side chains of the pore-lining residues are shown in sticks. Blue, green, and red spheres define radii of .3.3 Å , 1.823.3 Å , and ,1.8 Å , respectively. k, Plot of pore radii as a function of distance along the pore axis. The C a position of 09Arg is set to zero.
ARTICLE RESEARCH the width of the strychnine-bound state (Fig. 2h-k) . Furthermore, by measuring the rotation angle w of the M2 helix, we see that the M2 helices have undergone anticlockwise rotations of 49u and 22u in the glycine-and glycine/ivermectin-bound states, respectively, relative to the strychnine-bound form, when viewed from the extracellular side of the membrane. Considering the tilt and rotation angles together, the M2 helix undergoes an outward rotation from the strychnine-to glycine-bound forms, enlarging both constriction sites. By contrast, the relatively smaller rotation in the glycine/ivermectin-bound state leads to a distinct repositioning of the cytoplasmic end of the M2 helix, as defined by measurements at 229Pro, resulting in a constriction of the pore to a radius of 2.5 Å , which is smaller than a hydrated chloride ion (Fig. 2k) .
To ground our interpretations of the GlyR structures in the context of physiological function, we performed two-electrode voltage clamp electrophysiology (TEVC) experiments. At intermediate (Fig. 3g) and saturating ( Fig. 3f ) glycine concentrations, current decays are small and slow, consistent with the notion that the GlyR EM construct is not prone to desensitization and that the glycine-bound structure is an open conducting state. Strychnine antagonizes the glycine currents (Fig. 3g ), in accord with the conclusion that the strychnine-bound structure is a closed non-conducting state. In the presence of glycine and ivermectin, we observe initial potentiation followed by pronounced decay (Fig. 3h) . In addition, block of the glycine/ivermectin current by picrotoxinin, an open channel blocker, is only ,20% on peak or steadystate currents. Thus, even though ivermectin initially enhances glycineinduced currents, we propose that the glycine/ivermectin-bound form represents an agonist/allosteric modulator-bound desensitized state or a partially open state with reduced susceptibility to picrotoxinin block. This is consistent with recent studies which suggest that desensitization in ELIC 33 involves constriction at the intracellular entrance of the pore and that the picrotoxinin-binding site in GlyR spatially overlaps the desensitization gate 34 . We can define a rubric for extant Cys-loop receptor structures by dividing the receptors into three groups (Extended Data Fig. 7a-d ):
(1) closed: strychnine-GlyR, apo-GluCl, 5-HT3R, nAChR; (2) partially open or desensitized-like: glycine/ivermectin-GlyR, glutamate/ ivermectin-GluCl, GABA A R; (3) open: glycine-GlyR. In group 1, the pores are restricted by 99Leu. However, they possess distinct M2 conformations as indicated by the rotation angle (w), perhaps reflective of their distinct states: antagonist/closed and resting/closed. In group 2, glycine/ivermectin-GlyR and glutamate/ivermectin-GluCl share similar pore profiles and M2 conformations, suggesting they represent similar physiological states, perhaps desensitized-like or partially open low-conductance states 35 . Despite a tighter restriction at the intracellular entrance, the pore properties of the GABA A R resemble that of glycine/ivermectin-GlyR. This is consistent with the suggestion that the GABA A R crystal structure reflects an agonist-bound desensitized state 29 . In contrast, the unique large pore size and distinct M2 orientation distinguish the glycine-GlyR structure and are consistent with it defining a fully open ion-conducting state.
Neurotransmitter-binding site
The neurotransmitter-binding site of Cys-loop receptors is located at the interface of two adjacent subunits, surrounded by the C loop 'thumb' from the (1) side and the 'back of the mitten' b-strands on the (2) side. Strychnine binds with a dissociation constant (K d ) of 98 nM (Fig. 3c ) and in the strychnine-GlyR structure, we observe strong density in the neurotransmitter-binding site (Fig. 3a) . The almond-shaped density hews to the shape of a strychnine molecule, whose ring I forms the tip and rings III to VII form the bulbous bottom. In this pose, the relative positions of strychnine and the side chain of the conserved Tyr218 are in harmony with the crystal structure of the AChBP-strychnine complex 36 . A possible hydrogen bond between the carbonyl oxygen of strychnine and Arg81, proximity of the same carbonyl to Thr220 (C loop), and sandwiching of strychnine's aromatic rings by Phe79 and Tyr218 further enhance interactions between the antagonist and receptor (Fig. 3a, b ). In addition, the mutation Tyr177Ala results in strychnine insensitive GlyRs, whereas Tyr177Phe does not 37 . Despite no direct interaction to strychnine, Tyr177 sterically restricts the B loop close to the neurotransmitterbinding pocket, thus explaining how a change in residue volume could indirectly perturb the binding site.
Glycine robustly activates the receptor with minimal or partial current decay upon prolonged application of agonist at intermediate or saturating concentrations, respectively (Fig. 3f, g ) and yields an EC 50 of 0.26 mM. Density associated with glycine is not discernible in either the glycine-or glycine/ivermectin-bound structures due to its low molecular mass. Nevertheless, mutational analysis indicates that strychnine binding determinants such as Thr220 and Tyr218 partially overlap with those of glycine [38] [39] [40] . In particular, the Tyr218Phe mutant is reported to produce a 480-fold reduction in glycine affinity 41 . By comparing the ECDs of the glycine-and strychnine-bound structures, we observe that the overall shape of the b-sheet forming the (2)-half of the binding pocket remain essentially unchanged (Fig. 4a) . In contrast, Arg81, which is involved in glutamate binding in GluCl 26 , exhibits substantial conformational changes (Fig. 5b, c) . We propose that Arg81, Thr220 and Tyr218, together with Ser145, Phe175 and Phe223, directly participate in the binding of glycine [41] [42] [43] . A central concept of the relationship between ligand binding and channel gating in Cys-loop receptors is that the conformation of the C loop thumb is correlated to the functional state of the receptor, that is, the C loop is 'open' in the antagonist-bound closed channel state and 'closed' in the agonist-bound open channel state [44] [45] [46] [47] [48] . To examine this hypothesis, we superimposed the (2)-subunit of our GlyR models with the glutamate/ivermectin-GluCl, apo-GluCl, GABA A R, 5-HT 3 R, and strychnine-AChBP structures and compared the size of their binding pockets by measuring the distance between the C loop and the right half of the pocket (Extended Data Fig. 7e ). We observed that antagonist-bound strychnine-GlyR and strychnine-AChBP structures possess more open C loops and remarkably larger binding pockets than the agonist-bound structures. In addition, the glycineGlyR structure shares a more similar pocket size and shape to the glutamate/ivermectin-GluCl than the apo-GluCl structure, consistent with glycine being bound in the glycine-GlyR structure.
Allosteric-binding site
Ivermectin is a GlyR allosteric modulator that potentiates glycineinduced currents (Fig. 3h) . In the glycine/ivermectin-bound structure, the wedge-shaped ivermectin inserts into the TMD interface of two adjacent subunits and interacts with hydrophobic residues in M3 of the (1)-subunit and M1 of the (2)-subunit (Fig. 3d, e) . It also probably forms hydrogen bonds with several residues, one of which is Arg287, a residue that enables a direct interaction between ivermectin and the pore-lining M2 helix. Mutations of Arg287 to Gln or Leu in the human a1 GlyR subunit reduce the sensitivity of the receptor to ivermectin by a factor of 20 and these substitutions are the most frequent mutants associated with hyperekplexia (Extended Data Fig. 9c ) 5, 16 . The potential interaction between Arg287 and ivermectin, together with the location of Arg287 on the M2 helix, explains why mutations at 287 perturb both ivermectin action and ion channel gating.
Unlike GluCl 26 , ivermectin is not required for GlyR activation. To probe the structural basis for this difference in function, we compared the binding pockets in both receptors (Extended Data Fig. 6 ). Whereas ivermectin binds similarly to both receptors, there are several notable differences. First, Arg287 in GlyR interacts with ivermectin, yet the corresponding residue in GluCl 26 is an asparagine (Asn264) and the side chain is positioned further from ivermectin. Second, Val296 in the M2-M3 loop of GlyR is an isoleucine (Ile273) in GluCl, whose larger side chain prevents the O6-oxygen of ivermectin from approaching the M2-M3 loop. Third, Gly237 in the M1 and Strychnine-, glycine-, and ivermectin/glycine-bound states are in blue, yellow, and red, respectively. a-c, Superimposition of the three GlyR structures using the ECD (residues 1-235), showing the motion of the TMD. Relative rotation angles of the pore-lining M2 are indicated. d, e, Conformational changes in the ECD-TMD interface upon transition from the glycine-(or glycine/ivermectin-) to the strychnine-bound states are shown viewed parallel to the membrane (d) and from the extracellular side (e). The displacement of the b8-b9 loop leads to a rotation of pre-M1/M1, pushing the lower half of M2 towards the pore axis; meanwhile, this displacement repositions the Cys loop through b10, which results in the coupling of the M2-M3 loop with the b1-b2 loop through the interaction between Pro291 and Thr70. Consequently, the upper half of M2 rotates outward. Ala304 in the M3 of GlyR are Ser217 and Gly281 in GluCl, respectively. In GlyR, the M3 residue (Ala) is larger than the M1 residue (Gly), effectively 'pushing' ivermectin towards M1, creating a larger interaction surface area between ivermectin and M1 compared to M3. This situation is reversed in GluCl, however, as the M1 residue (Ser) is larger than the M3 residue (Gly). This is consistent with the experiments where the Ala304Gly substitution in the M3 strikingly enhanced the ivermectin sensitivity of human a 1 GlyR 49 , probably by enlarging the ivermectin-M3 interface.
Signal transduction
By superimposing a single subunit from the strychnine-and glycinebound states, we see that the b-sheets and flanking loops of the ECD behave like a malleable 'palm', undergoing a 'flexing-like' conformational change that is distributed throughout the entire domain, thus defying the demarcation of a simple local hinge (Fig. 4a) . The superposition also reveals that binding of ivermectin does not cause significant conformational changes of the ECD and ECD-TMD interface (Fig. 4b, c) . In the following comparison of the ECD and ECD-TMD interfaces, the glycine/ivermectin-GlyR structure, whose reconstruction is of better quality, is used (Figs 4d, e and 5). By contrast, the TMD behaves as an approximate rigid body upon comparison of the three structures (Extended Data Fig. 8 ). The M3-M4 loop is on the cytoplasmic side of the TMD, is truncated in this GlyR EM construct, and may have an effect on the conformational changes of the TMD. Further studies are necessary to clarify the role of the M3-M4 loop in receptor gating. Nevertheless, when we analyse the ECD interface in the strychnine-and glycine-bound states by superposition using the ECD of the (2)-subunit (Fig. 5a) , the 'flexing' of the b-sheets leads to prominent conformational changes in two critical regions-the interfaces between the ECDs that span the crevices between the orthosteric and allosteric agonist-binding sites, and the interfaces between the ECD and the TMD.
At the neurotransmitter-binding site, we observed an expansion in the strychnine-bound structure caused by displacement of Arg81 and Arg135 on the core of the b-sheet in the (2)-subunit and by the opening of the C loop, as indicated by the outward movement of Thr220 C a by 4 Å (Fig. 5b, c) . The motion of the C loop is mainly a consequence of the movement of the entire ECD, as also observed in GluCl 27 , together with a subtle 'flexing' at the loop tip. At the ECD-TMD interface, in the strychnine-bound closed state, there are extensive interactions between subunits at the interface near the ECD-TMD boundary 50 , defined by interactions between the b1-b2 loop, Cys loop, and M2-M3 loop of the (1)-subunit with the b1-b2 loop, b8-b9 loop, and pre-M1/M1 of the (2)-subunit. There are also multiple contacts between subunits within the TMD, mediated by intersubunit interactions between the M1 and M3 helices, and between M2 helices. By contrast, in the glycine-bound state, the interactions between subunits at the ECD-TMD boundary have largely ruptured, simply due to an increase in the separation of subunits, and the contacts between the TMD have also diminished by more than 50% (540 Å 2 in strychnine-GlyR and 240 Å 2 in glycine-GlyR), also because the subunits have moved apart. Remarkably, the increase in the separation of the intersubunit M1-M3 interaction in the glycinebound state provides the initial 'indentation' of the cavity that is occupied by ivermectin in the glycine/ivermectin complex.
To further understand how the conformational changes within the ECD are transduced to the TMD, we divided the M2 helix into upper and lower halves and followed their movements. On the one hand, the upper half of M2 couples to both the b1-b2 loop and Cys loop through the M2-M3 loop (Fig. 4d, e) in the glycine-bound form. The Cys loop further interacts with pre-M1/b10, the latter of which moves along with the b8-b9 loop. On the other hand, the lower half of M2 is connected to M1, which is coupled to the b8-b9 loop through the pre-M1 loop. Thus, the movement of M2 can be traced to the b8-b9 loop, a loop that, in turn, not only connects to the C loop covering the binding pocket but also sits underneath the pocket and thus indirectly participates in the binding pocket of the adjacent subunit (Fig. 5b) . In going from the strychnine-to glycine-bound states (Figs 4d, e and 5b, c), the C loop thumb switches from 'open' to 'closed' and the b8-b9 loop is displaced. This leads to a concomitant rotation of pre-M1 and M1, thus pushing the lower half of M2 towards the pore axis. Meanwhile, the b8-b9 loop repositions the Cys loop through b10, which results in the interaction of the M2-M3 loop with the b1-b2 loop causing an outward rotation of the upper half of M2.
Particularly important are the interactions at the ECD-TMD interface, where the b1-b2 and Cys loop of the (1)-subunit, together with the b8-b9 loop and pre-M1/M1 of the (2)-subunit, interact with the crucial M2-M3 loop of the (1)-subunit (Fig. 5d, e) . Here, in the strychnine-bound form, we suggest that Ser294 in the M2-M3 loop of the (1)-subunit stabilizes the channel in a closed conformation by capping the amino terminus of the M1 helix of the (2)-subunit (N-cap), making van der Waals contacts with residues in the pre-M1/ M1 region and participating in interactions with residues at the b8-b9 loop tip. Upon binding of glycine, the M2-M3 loop moves away from capping the amino terminus of the M1 helix and instead interacts with the b1-b2 loop via Pro291 and Thr70, stabilizing the channel in an open form. Several startle disease mutants in the M1 helix and the M2-M3 loop cause spontaneous activation of the receptor, perhaps by disruption of the interactions between Ser294 and the M1 N-cap (Extended Data Fig. 9a, b) 10 . Comparisons of the glycine-and glycine/ivermectin-bound structures reveal that binding of ivermectin causes the most notable changes at the cytoplasmic half of the TMD by 'tilting' the lower half of the M2 helix towards the pore lumen by 4.5u (Fig. 4c) , contracting the intercellular opening of the ion channel pore at 229Pro (Fig. 2j, k) . However, the extracellular regions of the pore in the glycine-and glycine/ivermectin-bound states are similar, possibly constrained by interactions of ivermectin with the M2 helix and the M2-M3 loops.
Gating mechanism
The strychnine-and glycine-bound structures of the GlyR, elucidated free from constraints of a crystal lattice or Fab fragments, unambiguously define antagonist-locked/closed and agonist-activated/open states of the receptor, respectively, while the glycine and ivermectin complex is suggestive of an allosteric modulator-bound low conductance or possibly desensitized state. A mechanism of ligand-dependent gating emerges from analysis of these structures in which the palm of the ECD and the forearm of the TMD are coupled by a flexible joint at the ECD-TMD interface, a joint reinforced by a ligament-like cuff glycine-, and glycine/ivermectin-bound states are in blue, yellow, and red, respectively. Comparison between strychnine-and glycine-GlyR (a), strychnine-and glycine/ivermectin-GlyR (b), glycine-, and glycine/ ivermectin-GlyR (c), viewed from the extracellular side. Side chains of 229Pro and 99Leu are shown in sticks to denote the change of pore sizes. In going from the strychnine-to the glycine-bound form, the TMD of each subunit undergoes an anticlockwise outward rotation, enlarging the pore size by pulling the side chains of 99Leu and 229Pro away from the channel axis. Binding of ivermectin to the glycine-GlyR causes a clockwise inward rotation of the TMD. As a result, although the extracellular half of the pore undergoes little change, the intracellular entrance shrinks.
composed of interacting ECD and TMD loops. Agonist binding closes the C loop thumb, promotes a concerted anticlockwise rotation around the pore axis (viewed from the extracellular side) of all 5 palm domains about an axis formed by finger-palm joints, and thus an iris-like expansion and anticlockwise rotation of the entire TMD 'forearms' (Fig. 6a-c and Supplementary Video 1). These structures not only allow us to describe a molecular mechanism for ligand-dependent gating in GlyRs, but also define a framework for interpreting the wealth of structural information on Cys-loop receptors and bacterial orthologues, which in turn will ground the search for new therapeutic agents on a solid structural foundation.
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METHODS

Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Receptor constructs. The gene encoding the zebrafish a1 glycine receptor (NP_571477) construct shares 92% amino acid similarity with the human a1 GlyR (Supplementary Fig. 1 ). The construct was chemically synthesized and further modified in accordance with the GluCl cryst construct, which involved removing 8 residues (Arg26-Pro33) from the amino terminus and 10 residues (Ile435-Gln444) from the carboxyl terminus, and replacing the long, highly variable M3/M4 loop (Gln334-Arg400) with the Ala-Gly-Thr tripeptide. This construct is named GlyR EM and was subcloned into the pFastBac1 vector for baculovirus expression in Sf9 insect cells. A thrombin cleavage site (Leu-ValPro-Arg-Ser) and an octa-histidine tag were introduced at the carboxyl terminus of GlyR EM . Expression and purification. The bacmid and baculovirus of GlyR EM in pFastBac1 were generated using standard methods 26 . GlyR EM P2 virus was used to infect Sf9 insect cells at 27 uC. At 72 h post-infection, the cells were collected and disrupted by sonication. The cell debris was removed by centrifugation at 8,000 r.p.m. 
Two-electrode voltage clamp electrophysiology (TEVC). The zebrafish a1
GlyR EM was subcloned into the pGEM vector for TEVC experiments. The RNAs were then transcribed using the mMessage mMachine T7 Ultra Kit (Ambion). Xenopus laevis oocytes were injected with 30 ng of mRNA and were incubated at 18 uC for 2-3 days in a solution containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES pH 7.5, and 250 mg ml 21 amikacin (incubation buffer). Borosilicate pipettes were filled with 3 M KCl. The stock solutions of strychnine and glycine were prepared in H 2 O at concentrations of 50 mM and 2 M, while ivermectin and picrotoxinin were solved in dimethyl sulfoxide (DMSO) at concentrations of 100 mM and 1 M, respectively. The ligands were solved in recording solution containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , and 5 mM HEPES pH 7.5. Recordings were performed at 260 mV. All recording experiments were performed three times independently. Half-maximal concentration of glycine (EC 50 ) and Hill coefficient (n H ) values were obtained using the Hill equation fitted with a nonlinear least squares algorithm using GraphPad Prism. The result was averaged from three independent experiments and the error bars represent s.e.m. Ligand-binding assays. The strychnine binding constant was determined by scintillation-proximity assay (SPA). Purified GlyR EM -His 8 (20 nM) was incubated with 1 mg ml 21 copper yttrium silicate (Cu-YSi) beads (Perkin Elmer) and 3 H-labelled strychnine (1:9 3 H: 1 H) in SEC buffer with a final volume of 100 ml. Non-specific binding was determined by the addition of 100 mM imidazole. Assay plates were read using a MicroBeta TriLux 1450 LSC and luminescence counter and data were fit to the Hill equation using GraphPad Prism. Crystallization and molecular replacement. GlyR EM was crystallized using the hanging-drop vapour-diffusion method in the presence of 2 mM glycine. One microlitre of protein solution (1.8 mg ml
21
) was mixed with 1 ml reservoir solution containing 30% PEG400, 0.1 M MES 6.5, and 0.2 M CaCl 2 . Diffraction data was collected on the 8.2.1 beamline at the Advanced Light Source of Lawrence Berkeley Laboratories (ALS), using a wavelength of 0.9762 Å . The data were indexed, integrated and scaled using XDS 51 . The space group is P2 The overall map quality of the pentamer A is better than that of the pentamer B. In pentamer A, the electron density is best for the transmembrane helices, where grooves and ridges can be observed. In contrast, the densities for extracellular domains are partially missing, likely caused by a lack of crystal contacts. Sample preparation and data acquisition for cryo-EM analysis. Purified GlyR EM in C 12 M was mixed with 10 mM glycine/5 mM ivermectin, with 1 mM strychnine or with 10 mM glycine a few hours before grid preparation. Next, 2.5 ml of protein sample at a concentration of 3.3 mg ml 21 was applied to a glow-discharged (10 s on each side) Quantifoil holey carbon grid (copper, 1.2 mM/1.3 mM hole size/hole space, 200 mesh), blotted using a Vitrobot Mark III (FEI company) using 3.5 s blotting time with 100% humidity, and then plungefrozen in liquid ethane cooled by liquid nitrogen.
The data sets were collected on a Titan Krios cryo-electron microscope (FEI company) at the CryoEM Facility at the Janelia Research Campus or on a Polara microscope (FEI) at UCSF. The data for the glycine/ivermectin-bound state was collected on Titan Krios I and the data for the strychnine-bound state was collected on Titan Krios II at Janelia. Krios I is equipped with a CETCOR Image Corrector for spherical aberration correction and a Gatan Image Filter (GIF). A 30 eV energy slit as well as a 70 mM objective aperture (corresponding to a cutoff of 2 Å ) was used during data collection. The Image Corrector tuned the C s from an original 2.7 to 0.01 mm. The data for the glycine-bound form was collected on the TF30 Polara at UCSF. All the microscopes are equipped with a field emission source and operated at 300 kV. Images were recorded on the Gatan K2 Summit direct electron detector operated in super-resolution counting mode. At Janelia the dose rate was 10e 2 per pixel per s, determined in 'empty' holes. At UCSF the dose rate was 10.9e
2 per pixel per s, determined through a layer of vitreous ice. The total exposure time was either 5 s or 6 s, with an accumulation time of 0.2 s for each frame. The dose-fractionated images were recorded using the automated acquisition program SerialEM or the semi-automated acquisition program UCSFImage4 (written by X. Li) at Janelia or UCSF, respectively. Nominal defocus values ranged from 21.5 to 22.5 mM or 21.5 to 23.0 mM (Extended Data Table 1 ). Image processing. Super-resolution counting images were 2 3 2 binned in Fourier space, resulting in a pixel size of 1.0400 Å (Krios I), 1.0100 Å (Krios II), or 1.2156 Å (Polara). Motion correction was done using MotionCorr 52 , with a B-factor of 250 or 1,000 pixels squared. All the motion-corrected frames (25 or 30) were summed to a single micrograph for subsequent processing with RELION 53 . Defocus values were estimated using CTFFIND3 (ref. 54) . For each data set, approximately 1,000 particles were manually picked for an initial reference-free 2D classification. Seven to eight representative 2D class averages were selected as templates for automated particle picking. The auto-picked particles were visually checked and false positives were removed. The particles were further cleaned-up by two rounds of 2D classification using RELION. An initial 3D model was generated from the GluCl crystal structure 26 (PDB code: 3RHW) and low-pass filtered to 50 Å using EMAN2 (ref. 55) . No symmetry was applied during 3D classification in RELION. Classes with characteristic features of Cysloop receptors were then selected. Particles belonging to the chosen classes were used for 3D auto-refinement using RELION, followed by 3D refinement with movie particles, in which the movement of each individual particle was determined. In the subsequent 'polishing' step, the movement of each particle was corrected. In addition, resolution-dependent radiation damage was modelled by performing a weighted average of all aligned movie frames for each particle, using a B-factor estimated by the polishing algorithm. The resulting 'shiny' particles were used for a final round of 3D classification and refinement. The polishing procedure typically increased the estimated resolution by 0.2-0.3 Å . Five-fold symmetry was applied during all refinement steps. In the post-processing step in RELION, a soft mask was calculated and applied to the two half-maps before the Fourier shell coefficient (FSC) was calculated. B-factor estimation and map sharpening were also performed in the post-processing step. The resolutions reported in Extended Data Table 1 are based on the gold standard FSC 0.143 criteria 56 . Further details related to data processing are summarized in Extended Data Table 1 . Model building. A molecular replacement solution from a low-resolution and incomplete X-ray diffraction data, using the GluCl structure (PDB code: 3RHW) as a search probe, was used as an initial model (see the crystallization and molecular replacement section). The mismatched residues are replaced with the correct ones using the SWISS-MODEL online server 57 . The resulting model was fit into the density map of the glycine/ivermectin-bound state using UCSF Chimera 58 . Further model building and real space refinement was done using COOT 59 . For the other GlyR structures, the glycine/ivermectin-bound structure was used as a starting model. Strict five-fold symmetry was used throughout model building and refinement. The final masked maps were put into P1 unit cells with cell dimensions equal to the box sizes used to extract particles (Extended Data Table 1 ) and structure factors were calculated using the program SFTOOLS in the CCP4 suite 60 . The resulting structure factors were used for maximum
RESEARCH ARTICLE likelihood refinement in reciprocal space using Phenix.refine with secondary structure and NCS restraints. For cross validation 61 , the refined structures were randomly displaced by 0.1 Å . The displaced models were then refined against one of the half maps produced by RELION following the same procedure described above. FSC curves were calculated between the refined model and half map 1 ('work', used for refinement), refined model and half map 2 ('free', not used for refinement), and the refined model and summed map. No significant separation of work and free FSC curves was observed, suggesting the atomic models were not over-refined. The geometries of the atomic models were evaluated using MolProbity 62 . Our models have the same helical registers as the crystal structures of GluCl and the GABA A and 5-HT 3 receptors, but differ by one turn from that of the 4 Å cryo-EM Torpedo AChR structure. All figures were prepared using Pymol (Schrödinger) 63 , UCSF Chimera and Prism 5 (GraphPad, La Jolla). Pore radii were calculated using the program HOLE 64 .
Extended Data Figure 1 | Three-dimensional reconstruction of strychninebound GlyR. a, A representative micrograph (out of 1,829 micrographs) of strychnine-bound GlyR in vitreous ice. b, c, Angular distribution of particle projections (b), and selected 2D classes (c) are shown. In c, the radius of the sphere is proportional to the number of particles assigned to it. The plot is drawn with respect to the 3D reconstruction shown in the centre, taking the C5 symmetry of the receptor into account. d, Selected 'slice' views of the final reconstruction along the pore axis. The slice numbers are indicated, starting from the intracellular side. e, FSC curves for the density maps before (red) and after (black) post-processing in RELION. The FSC curve between the refined atomic model and the final reconstruction map is shown in green. f, FSC curves for cross-validation: model versus summed map (full data set, green), model versus half map 1 (used in test refinement, orange) and model versus half map 2 (not used in test refinement, purple). g, Unfiltered and unsharpened 3D density map coloured according to local resolution estimated using RESMAP 65 . h, Real-space correlation between atomic model and density map calculated using PHENIX.
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Extended Data Figure 2 | 3D reconstruction of glycine-bound GlyR. a, A representative micrograph (out of 1,460 migrographs) of glycine-bound GlyR in vitreous ice. b, c, Angular distribution of particle projections (b) and selected 2D classes (c) are shown. In c, the radius of the sphere is proportional to the number of particles assigned to it. The plot is drawn with respect to the 3D reconstruction shown in the centre, taking the C5 symmetry of the receptor into account. d, Selected 'slice' views of the final reconstruction along the pore axis. The slice numbers are indicated, starting from the intracellular side. e, FSC curves for the density maps before (red) and after (black) post-processing in RELION. The FSC curve between the refined atomic model and the final reconstruction map is shown in green. f, FSC curves for cross-validation: model versus summed map (full data set, green), model versus half map 1 (used in test refinement, orange) and model versus half map 2 (not used in test refinement, purple). g, Unfiltered and unsharpened 3D density map coloured according to local resolution estimated using RESMAP. h, Real-space correlation between atomic model and density map calculated using PHENIX.
Extended Data Figure 3 | 3D reconstruction of glycine/ivermectin-bound GlyR. a, A representative micrograph (out of 2,489 micrographs) of glycine/ ivermectin-bound GlyR in vitreous ice. b, c, Angular distribution of particle projections (b) and selected 2D classes (c) are shown. c, The radius of the sphere is proportional to the number of particles assigned to it. The plot is drawn with respect to the 3D reconstruction shown in the centre, taking the C5 symmetry of the receptor into account. d, Selected 'slice' views of the final reconstruction along the pore axis. The slice numbers are indicated, starting from the intracellular side. e, FSC curves for the density maps before (red) and after (black) post-processing in RELION. The FSC curve between the refined atomic model and the final reconstruction map is shown in green. f, FSC curves for cross-validation: model versus summed map (full data set, green), model versus half map 1 (used in test refinement, orange) and model versus half map 2 (not used in test refinement, purple). g, Unfiltered and unsharpened 3D density map coloured according to local resolution estimated using RESMAP. h, Real-space correlation between atomic model and density map calculated using PHENIX.
Extended Data Figure 6 | Comparison of ivermectin-binding site in GlyR (red) and GluCl (green). a, Viewed in parallel to the membrane. b, Viewed from the extracellular side. The (1)-subunits are shown in darker colours. The residue corresponding to Arg287, which forms a hydrogen bond with the ivermectin in GlyR, is an asparagine (Asn264) in GluCl. The corresponding residue of Val296 in the M2-M3 loop of GlyR is an isoleucine (Ile273) in GluCl, whose larger side chain prevents the upper tip of ivermectin from approaching and interacting with the main chain oxygen atom of Ser721 in the M2-M3 loop (Ser294 in GlyR). The Gly237 in the M1 and Ala304 in the M3 of GlyR are Ser217 and Gly281 in GluCl, respectively. Such differences on side chains weaken or strengthen the interaction of ivermectin with M3 or M1 in GlyR, respectively, in comparison to that in GluCl.
Extended Data Figure 7 | Comparison of GlyR with other Cys-loop receptors. a, The two restriction sites, viewed from the cytoplasmic side. The C a of 229Pro equivalents (cyan) and 99Leu equivalents (magenta) are shown as spheres. Distances between adjacent C a atoms are labelled. b, Plot of the vector connecting the 229ProC a equivalent and 99LeuC a equivalent, with 22ProC a equivalent as the origin, the tilt angle h and the rotation angle w relative to the pore axis. The w of strychnine-bound GlyR is arbitrarily set to zero. c, Pore radii as a function of distance along the pore axis, calculated using the program HOLE, where the C a position of 09Arg is set to zero. d , Table  showing parameters of the vector connecting the 229ProC a equivalent and 99LeuC a equivalent, where r is the distance from 229ProC a equivalent to 99LeuC a equivalent, Restr P and Restr L are the pore radii at 229Pro equivalent and 99Leu equivalent, respectively. The d C loop is the distance between C a of Thr220 equivalent and Leu143 equivalent, representing the opening of the C loop shown in e. e, Comparison of ligand-binding pockets. The side chains of marker residues are shown in stick format.
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G2015 Macmillan Publishers Limited. All rights reserved Extended Data Figure 8 | Superimposition of TMD in three GlyR structures using main chain atoms of residues Met236-Lys362. a, Between strychnineand glycine-GlyR. b, Strychnine-and glycine/ivermectin-GlyR. c, Glycineand glycine/ivermectin-GlyR. The M2-M3 loop, residues Ser289-Ala298, is excluded from the comparison. The root mean square deviations (r.m.s.d.) are 0.9, 0.9, and 0.7 Å , respectively, suggesting that the movement of the TMD is rigid-body-like. Most differences are located in the termini of transmembrane helices, which are either close to the M2-M3 loop, or close to the intracellular gate 229Pro.
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Extended Data Figure 9 | Positions of residues in which mutations are associated with human startle disease. Residues that likely interact with disease-causing residues are labelled in italics. a, The strychnine-GlyR model is used to show residues in which mutations cause spontaneous activation. The mutation of Gln242 in M1 to glutamate may enhance its electrostatic attraction to Arg287 in M2 of the adjacent subunit and tilt the upper part of M2 away from pore axis, resulting in a constitutively open channel. Alternatively, the mutation Val296Met in M2-M3 loop may cause steric collision with Ile241 in M1 of the adjacent subunit, and prevent Ser294 from interacting to the N-cap formed by pre-M1, M1 and the b8-b9 loop, thereby destabilizing the closed conformation. b, The glycine/ivermectin-GlyR model is used to show residues in the ECD-TMD interface whose mutations reduce sensitivity to glycine and single channel conductance. The mutation of Arg234 in pre-M1 to glutamine may disturb its electrostatic interaction with Asp164 in the Cys loop. Similarly, the mutation of Tyr295 in the M2-M3 loop to cysteine or serine may disturb its interaction with the main chain nitrogen atom of Leu158 in the Cys loop. In both cases, the signal induced by agonist binding may be blocked. The mutation Lys292Glu in the M2-M3 loop possibly affects the cooperative interaction between two adjacent subunits by altering the van der Waals contacts between Lys292 and Tyr238. c, The glycine-GlyR model is used to show residues in M2 in which mutations reduce sensitivity to glycine and diminish single channel conductance. These mutations may directly influence the pore properties by modifying the interactions with adjacent residues, for instance, between Gln282His and Pro246, and between Arg287Gln/Leu and Gln242.
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